Autolus Therapeutics plc (AUTL) posted Q4 2025 Basic and diluted net loss per ordinary share EPS of -$0.34. Revenue totaled $24.3M for the quarter. Revenue of $24.3M was up 83655.2% year-over-year.
Autolus Therapeutics plc is a Biotechnology company. AUCATZYL net product revenue was 74.3 Mn dollars for the quarter. Bottom line showed a net loss of $90.3M.
Revenue guidance for the full year was set at $120.0M to $135.0M. Wall Street consensus stands at 17 buy, 1 hold, 0 sell. That compares to -$0.10 a year ago, a 240.0% decrease. Revenue was up 83655.2% from $29,000 in Q4 2024.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.